About US
Contact us
-
Regeneron advances antitrust lawsuit against Novartis with appeals court's backingDid Novartis break U.S. antitrust laws in the storied Eylea-Lucentis rivalry? Thanks to an appeals court ruling, Regeneron has another chance to lay out its argument. The U.S. Court of App2024/3/1
-
GSK inks another Zantac settlement ahead of trial in CaliforniaAfter GSK spent the latter half of 2023 warding off concerns about the swelling Zantac product liability litigation, the company is back at the settlement table in 2024. Thursday, GSKsaidit has reach2024/2/2
-
Astellas inks deal to air Veozah ad in Super Bowl 2024 coverageAstellas is continuing its Veozah marketing blitz, signing up to air an ad for the drug just before kickoff in the upcoming Super Bowl to push the treatment of menopause-related vasomotor symptoms (V2024/2/2
-
Teva's refresh under new CEO Richard Francis moves into year 2 as Austedo, Ajovy and generics gain steamAfter charting a series of sales increases in 2023, Teva’s largely made good on the promise of its new CEO’s “Pivot to Growth” campaign. With group revenues on the up and up, it’s all about maintaini2024/1/30
-
In continuing its transformation, Teva confirms plan to sell off API businessTeva’s transformation under new CEO Richard Francis is taking another turn. Wednesday, the companyconfirmedplans to sell its active pharmaceutical ingredients business as part of Francis’ “pivot to g2024/1/30
-
GSK confirms Arexvy is a blockbuster but says the RSV battle has just begunBeaten to the punch by Pfizer in developing a vaccine for COVID, GSK has regained some of its lost luster as a vaccine powerhouse with its advancement of respiratory syncytial virus (RSV) shot Arexvy2024/1/25
-
As AstraZeneca gears up for courtroom showdown over IRA, Novo's case faces separate HHS rebukeWhen the Biden administration welcomed the passing of the Inflation Reduction Act (IRA) in August 2022, it marked a rare defeat for the pharmaceutical industry in Washington, D.C. Naturally, drugmake2024/1/25
-
Regulatory tracker: Bristol Myers filings for Breyanzi gain FDA priority reviewsWelcome to 2024's regulatory tracker for Fierce Pharma. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Som2024/1/23
-
Gilead's Kite wins FDA nod for new CAR-T manufacturing process to speed up Yescarta turnaroundEver since the first CAR-T launches several years ago, lengthy manufacturing timelines have been one drawback of this promising drug class. But with a new FDA blessing, Gilead Sciences is expediting2024/1/23
-
Pfizer's layoff campaign ramps back up with dozens of SF-area cuts expected next monthThe start of the new year doesn’t seem to have dulled the zeal of Pfizer’s global cost-cutting campaign, which has already left hundreds of jobs in its wake. Come mid-February, Pfizer will lay off so2024/1/18